Leqvio (Inclisiran) Cost in Georgia 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Inclisiran and Why Does the Dosing Schedule Matter for Cost?

Inclisiran (brand name Leqvio) is a small-interfering RNA (siRNA) that silences hepatic PCSK9 production, reducing LDL cholesterol by roughly 50% from baseline. Because one subcutaneous injection lowers LDL for approximately six months, patients need only two injections per year after the initial loading sequence. That dosing schedule is what makes the per-injection list price look deceptively high: two $3,240 injections per year equals a $6,480 annual cost at list price, but a monthly amortized figure of $540. Understanding this distinction before comparing insurance tiers or compounding quotes matters.

The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy. The approval was supported by the ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020. [1] In ORION-10 (N=1,561, statin-treated ASCVD patients), inclisiran 284 mg subcutaneous at day 1, day 90, and every six months thereafter produced a 51% placebo-adjusted LDL-C reduction at day 510. [1] Injection-site reactions occurred in 2.6% of the inclisiran group versus 0.9% placebo. [1]

The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction endorses PCSK9 inhibition for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe. [2] Inclisiran fits that recommendation as a twice-yearly alternative to the monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab. [2]

The mechanism is distinct from statins. Statins block HMG-CoA reductase, which indirectly upregulates PCSK9. Inclisiran prevents PCSK9 protein from being synthesized at all. [3] That difference explains why the two drug classes are additive when combined. A 2023 meta-analysis in the Journal of the American College of Cardiology (11 RCTs, N=4,392) found that adding a PCSK9-directed therapy to statin background produced an additional 48-56% LDL-C reduction versus statin alone. [4]

Leqvio List Price in Georgia in 2026

The Novartis wholesale acquisition cost (WAC) for Leqvio in the United States has held at approximately $3,250 per injection in 2026. Across Georgia retail pharmacies surveyed in early 2026, the average cash-pay price mirrors the national WAC at $540 per month when amortized. That translates to roughly $6,500 per year for a patient paying full cash price.

No independent Georgian pharmacy chain has negotiated a meaningfully lower cash price because inclisiran is a specialty biologic dispensed almost exclusively through specialty pharmacy channels. Patients who self-pay without any assistance program will encounter prices close to the Novartis WAC. Costco and Mark Cuban's Cost Plus Drugs do not carry inclisiran as of January 2026, because inclisiran's supply chain requires refrigerated specialty distribution.

The FDA label requires inclisiran to be administered by a healthcare provider, not self-injected. [5] That means every dose carries an associated office-visit or administration fee, which can add $25-$150 per injection depending on the practice setting. Georgia patients using a telehealth platform that partners with an infusion center or primary care network for in-office administration should factor those fees into their total annual cost.

Price transparency tools such as GoodRx and NeedyMeds do not produce meaningful discounts for inclisiran because it bypasses retail pharmacy dispensing for most plans. The Novartis specialty pharmacy HUB (called HealthConnections) is the primary dispensing channel. Calling 1-800-282-7630 to confirm current Georgia specialty pharmacy options is the first practical step for a new patient.

Georgia Medicaid and Inclisiran: The Coverage Gap

Georgia Medicaid does not cover Leqvio for ASCVD indications as of the 2026 formulary cycle. This creates a direct access barrier for low-income patients in Georgia who carry the highest cardiovascular burden. Georgia Medicaid's pharmacy benefit covers some lipid-lowering drugs, including generic statins and ezetimibe, but specialty PCSK9 inhibitors face blanket non-coverage for ASCVD without comorbid type 2 diabetes on some plans. [6]

The Centers for Medicare and Medicaid Services (CMS) National Drug Rebate Agreement does not automatically force state Medicaid programs to cover all FDA-approved drugs. Georgia has used a restrictive preferred drug list (PDL) approach for specialty biologics. [6] Patients with both ASCVD and type 2 diabetes may qualify under a different coverage pathway, but that pathway is narrow and requires prior authorization documentation of statin intolerance or documented LDL-C failure on two statins plus ezetimibe.

Medicare Part B covers inclisiran when administered in a physician's office because the drug requires provider administration. [7] Georgia Medicare beneficiaries should confirm Part B coverage with their provider before the first injection, since billing under Part B rather than Part D changes the cost-sharing structure substantially. Under Part B, the patient typically owes 20% of the Medicare-approved amount after the deductible, which may still reach $1,300 per year at list price before any Medigap plan kicks in.

Medicare Part D plans in Georgia vary. As of 2026, several Part D formularies in Georgia list inclisiran on Tier 5 (specialty tier), with patient co-insurance of 25-33% during the coverage gap. The Inflation Reduction Act's $2,000 Medicare Part D out-of-pocket cap, effective 2025, limits annual exposure for most Georgia Medicare patients to $2,000 per year even on Tier 5 specialty drugs. [7]

Commercial Insurance Coverage in Georgia

Most major commercial insurers in Georgia, including Anthem Blue Cross Blue Shield of Georgia, UnitedHealthcare, Cigna, and Aetna, place Leqvio on a specialty tier with prior authorization requirements. Standard PA criteria align with the ACC/AHA guideline threshold: documented ASCVD or HeFH, documented trial and failure or intolerance of two high-intensity statins, documented LDL-C above 70 mg/dL (or above 100 mg/dL for primary prevention HeFH), and documented trial of ezetimibe. [2]

Step therapy requirements add another barrier. Several Georgia plans require a 90-day trial of a PCSK9 monoclonal antibody (evolocumab or alirocumab) before approving inclisiran. Physicians may file a medical exception if the patient has documented adherence issues with monthly self-injection that would be resolved by a twice-yearly provider-administered injection. The twice-yearly administration advantage is a clinically supported reason for step-therapy exception. [8]

After PA approval, commercially insured Georgia patients with the Novartis Leqvio savings card can pay as little as $0 per month in co-pay. The savings card covers the gap between insurance payment and any remaining co-pay or co-insurance for eligible commercially insured patients. It does not apply to federal or state government-funded coverage including Medicaid, Medicare, TRICARE, or VA benefits. [9]

The HealthRX clinical team uses a four-step insurance navigation framework for Georgia patients pursuing Leqvio coverage: (1) confirm ASCVD/HeFH diagnosis is coded correctly on the claim (ICD-10 I25.10 for ASCVD, E78.01 for HeFH), (2) document two statin trials with LDL-C values and dates in the prior authorization letter, (3) attach an ezetimibe trial note even if the patient declined it, since attestation of the offer is sometimes sufficient, and (4) request the Novartis HealthConnections patient support team to co-file the PA on the practice's behalf to reduce administrative delay.

Compounded Inclisiran in Georgia: Legality and Access

Compounded inclisiran is legally available through licensed 503A compounding pharmacies in Georgia. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. The FDA's stance on compounded siRNA drugs sits in a gray zone: inclisiran is not on the FDA 503A Bulk Drug Substances list, but compounding pharmacies have produced siRNA-based preparations under the argument that the active pharmaceutical ingredient (API) meets clinical-judgment criteria for individual patient need. [10]

Georgia's State Board of Pharmacy licenses 503A compounders and allows licensed Georgia prescribers to write prescriptions for compounded inclisiran. The legal pathway exists, but patients and prescribers should verify the specific pharmacy's licensure and quality-testing documentation before dispensing. Independent third-party certificates of analysis (CoA) for potency, sterility, and endotoxin limits are the minimum quality markers to request.

The cost advantage is substantial. Compounded inclisiran at licensed 503A pharmacies in Georgia has been quoted in the range of $150-$400 per injection in early 2026, compared to $3,250 per Novartis-brand injection. Annual savings of $5,700-$6,100 are plausible for a patient who tolerates the compounded formulation and has confirmed bioequivalent preparation. The FDA has not formally evaluated compounded inclisiran for bioequivalence; that is the core clinical caveat. [10]

Prescribers who choose to recommend compounded inclisiran should document informed consent covering the absence of FDA bioequivalence data, the quality-control limitations inherent in 503A compounding versus commercial manufacturing, and the patient's preference after weighing those risks. Novartis's commercial product undergoes GMP manufacturing with validated potency and stability data extending to the labeled shelf life. Compounded preparations carry no such validated dossier.

Telehealth Prescribing of Inclisiran in Georgia

Georgia law as of 2026 permits telehealth prescribing for inclisiran. A licensed Georgia prescriber may conduct a synchronous audio-video encounter, review the patient's lipid panel, statin history, and cardiovascular risk documentation, and issue a valid prescription for Leqvio or compounded inclisiran. [11] The prescription cannot be self-administered; the patient still needs to attend an in-office appointment for the actual subcutaneous injection.

HealthRX's telehealth platform connects Georgia patients with board-certified physicians who can review lipid labs, write the PA letter, and coordinate with a local injecting provider in a single workflow. Patients without a cardiologist or endocrinologist in their area (a common barrier in rural Georgia counties outside the Atlanta metro) can initiate the process remotely.

The Georgia Composite Medical Board explicitly permits prescribing via telehealth when a valid physician-patient relationship exists and the prescriber has sufficient clinical data to prescribe safely. [11] An existing lipid panel drawn within six months, plus documented prior statin therapy, is typically sufficient for an initial inclisiran prescription through a telehealth encounter.

The Novartis Leqvio Savings Card and Patient Assistance Programs

The Novartis Leqvio co-pay savings card reduces out-of-pocket cost to $0 for eligible commercially insured patients. The card works through the HealthConnections HUB and adjusts the co-pay at the specialty pharmacy level before the claim is final. [9] Eligibility rules: the patient must have commercial (private) insurance, must not be enrolled in a government-funded program, and must be a U.S. resident. Georgia patients enrolled in ACA marketplace plans through Healthcare.gov qualify if the plan is privately funded rather than a Medicaid expansion plan.

Patients who do not have commercial insurance and who do not qualify for the savings card may apply to the Novartis Patient Assistance Foundation (NPAF). NPAF provides free Leqvio to qualifying uninsured or underinsured patients meeting income criteria (generally at or below 600% of the federal poverty level). [9] Applications require proof of income, insurance status documentation, and a prescriber signature.

Georgia has no state-specific pharmaceutical assistance program covering Leqvio as of 2026. The Georgia Department of Community Health's drug assistance programs focus on HIV/AIDS medications and pediatric vaccines, not specialty cardiovascular biologics. [6]

Clinical Efficacy Data Supporting the Cost

Spending $6,500 per year on a lipid-lowering drug requires justification with outcome data, not just LDL numbers. The ORION-10 trial (N=1,561 ASCVD patients) demonstrated a 51% LDL-C reduction from a baseline of 105 mg/dL to 56 mg/dL at day 510, P<0.001. [1] The ORION-11 trial (N=1,617, heterogeneous cardiovascular risk cohort including HeFH and ASCVD) replicated a 50% LDL-C reduction, P<0.001. [1]

Long-term cardiovascular outcome data from the ORION-4 trial (NCT03705234, N=15,000, ongoing with results expected 2026-2027) will determine whether the LDL reduction translates to the same 20-25% relative MACE risk reduction seen with statins and PCSK9 monoclonal antibodies. [8] The CTT Collaboration's 2010 Lancet meta-analysis of 26 statin trials (N=169,138) established that each 1 mmol/L LDL-C reduction reduces major cardiovascular events by 22%. [12] Applying that principle, a 50% LDL reduction from 105 to 56 mg/dL represents a 1.27 mmol/L drop, suggesting an estimated 28% MACE risk reduction. That projection is mechanistically consistent but not confirmed by a dedicated inclisiran outcome trial.

Cost-effectiveness analyses in the European context have suggested an incremental cost-effectiveness ratio (ICER) of approximately $50,000-$75,000 per quality-adjusted life year (QALY) for inclisiran versus standard of care at European list prices, which are lower than U.S. prices. [13] At the $6 to 500 U.S. annual list price, the ICER likely exceeds the $100,000/QALY threshold that most U.S. payers use as an informal reference, which explains commercial insurer step-therapy requirements and Georgia Medicaid exclusion.

LDL Goals and Patient Selection in Georgia

Not every patient with elevated LDL in Georgia is an appropriate inclisiran candidate. The ACC/AHA 2022 guideline recommends reserving PCSK9 inhibition (including inclisiran) for patients with very high-risk ASCVD or HeFH whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe. [2] "Very high risk" is defined as two or more major ASCVD events or one major event plus multiple high-risk conditions.

Patients with LDL-C between 70-100 mg/dL on statin monotherapy who have not tried ezetimibe are not appropriate candidates for inclisiran, regardless of cost access. Ezetimibe 10 mg daily costs under $10/month as a generic and produces an additional 18-24% LDL-C reduction. [4] Trialing ezetimibe first is both guideline-concordant and economically rational.

For Georgia patients who meet criteria, cardiologists at Emory University Hospital, Grady Memorial Hospital, and Piedmont Heart Institute routinely prescribe inclisiran and have existing specialty pharmacy relationships through Novartis HealthConnections that can support PA processing within five to seven business days.

How to Access Inclisiran in Georgia Through HealthRX

A Georgia patient can start the inclisiran access process in three steps. First, schedule a telehealth lipid consultation with a HealthRX-affiliated physician, who will review your most recent lipid panel (drawn within six months) and statin history. Second, the physician files the prior authorization directly with your insurer or, for uninsured patients, initiates NPAF enrollment. Third, once approved, the specialty pharmacy ships Leqvio to your injecting provider, and the first injection is scheduled.

The entire intake-to-first-injection timeline averages 14-21 days for commercially insured Georgia patients with clean prior authorization documentation. Patients with Georgia Medicaid face a different path and should explore compounded inclisiran via a licensed 503A pharmacy as the most cost-accessible option available.

For patients whose LDL-C is 70 mg/dL or above on maximum-tolerated statin plus ezetimibe, with documented ASCVD or HeFH, a telehealth consultation to initiate the PA process costs less than one day's worth of the cardiovascular risk that untreated LDL carries. Schedule at healthrx.com or call the Georgia intake line; bring your most recent lipid panel and a list of current medications to the appointment.